Referring Clinicians

Trials Recruiting at ACTC 

Tumour StreamTrial NameStudy DescriptionKey Investigational AgentKey Inclusion CriteriaRecruitment Status
Advanced Solid Organ TumoursGILEAD (GS-US-494-5484)A Phase 1b/2 Dose Escalation/Expansion Study to Evaluate the
Safety, Tolerability, Pharmacokinetics, and Efficacy of GS-4224 in
Subjects with Advanced Solid Tumors
GS-4224 (small molecule oral PDL1 Inhibitor)
Daily doing, 3 week cycles
Advanced Solid Organ Malignancy with no further treatment options.

TPS/CPS >10% on pre-screening of archival tissue for biopsy sub-study
Biopsy sub-study Recruiting

Dose Escalation: Recruitment intermittent
NSCLC, Oesophageal SCCNP40435Phase 1b study to evaluate safety, pharmacokinetic and preliminary anti-tumour activity of R07121661, PD-l/TIM3 Bispecific Antibody in patients with advanced and/or metastatic solid tumoursPD1/TIM3 bi-specific antibody

2 weekly infusions
-NSCLC: CPI experienced, post platinum, must have received at least 4 months of CPI, PDL1>1%

- Oesophageal: squamous or adeno-squamous, not more than 1 line of treatment for metastatic disease or recurrence within 24 weeks after chemo-RT/ surgical resection.
Recruiting
CervicalAK104-201-AUA Phase 2, global, multicenter, open-label, single-arm study designed to evaluate the efficacy, safety, tolerability, pharmacokinetic (PK), and immunogenicity of AK104 monotherapy in adult subjects with previously treated recurrent or metastatic cervical carcinoma.AK104
(bispecific antibody targeting CTLA4/ PD-1)

Fortnightly infusion
•Previously treated recurrent or metastatic squamous carcinoma or adeno-squamous carcinoma of the cervix:
o Disease progression during or following platinum doublet
o No more than 2 prior systemic therapies in recurrent/ metastatic setting
o Not eligible for surgery or radiation as treatment for recurrent disease
o Available archival tissue for PD-L1 assessment.
Recruiting
Part 1: Melanoma, Urothelial carcinoma

Prt 2: NSCLC, RCC
CA20976UA Phase 1/2 Pharmacokinetic Multi-tumor Study of Subcutaneous Formulation of Ipilimumab
Monotherapy and in Combination with Subcutaneous Nivolumab
S/C Ipilimumab monotherapy followed by combination with S/C Nivolumab

(with recombinant human hyaluronidase)
2-3 weekly infusions
Part 1
o Melanoma: IO naïve stage IV, prior BRAF/ MEK targeted therapy permitted.
o Urothelial Carcinoma: metastatic or surgically unresectable disease, progression or refractory disease after at least 1 platinum-based chemo regimen (recurrence within 1 year of completing treatment)

Part 2
o Metastatic NSCLC: Opening soon. Treatment naïve stage IV . Prior adjuvant chemo +/- RT allowed as long as > 6 months from time of completion.
o RCC: No prior treatment lines for stage IV or recurrent disease, IMDC intermediate and poor risk only.
Part 1: recruiting but closing soon.
Part 2: opening soon
Advanced solid tumours with established IO indicationBGB-A317-A445-101Phase 1 Study Investigating the Safety, Tolerability,
Pharmacokinetics, and Preliminary Antitumor Activity of the
Anti-OX40 Agonist Monoclonal Antibody BGB-A445 in
Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab
in Patients With Advanced Solid Tumors
BGB-A445 (OX40 agonist) and Tislelizumab (PD-1 inhibitor)

Three weekly infusions
• Phase 1a: Dose Escalation: Includes BGB-A445 monotherapy cohorts and combination cohorts with tislelizumab. Recruitment opens intermittently.

• Dose Expansion: Closed until phase 1a completed. Details to follow.
Phase 1a recruiting

How to Refer 

Please email all referrals to CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)

Email us for any other inquiries: infoACTC@adhb.govt.nz

 

Auckland Cancer Trials Centre

Auckland City Hospital,

2, Park Road, Grafton,

1023, Auckland, New Zealand

Patient Referrals 

Please email all referrals to: CentralReferrals@adhb.govt.nz (include Att: ACTC in email subject)

Email us for any other inquiries:

infoACTC@adhb.govt.nz